DNTH NASDAQ
Dianthus Therapeutics, Inc.
1W: +1.0%
1M: -9.5%
3M: -23.6%
YTD: +100.4%
1Y: +141.6%
3Y: +539.7%
5Y: -22.1%
$79.52
+0.19 (+0.24%)
After Hours: $80.54 (+1.02, +1.28%)
Weekly Expected Move ±5.4%
$69
$73
$77
$81
$85
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.44B.
Distance to default 14.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.5%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.44B.
Distance to default 14.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.5%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#70
of 1060
Biotechnology
Technical Signal Map
70 Bullish
12 Neutral
79 Bearish
DNTH
$4.3B
Dianthus Therapeutics, Inc.
BEARISH
-52
LZAGY
$54B
Lonza Group AG
BULLISH
+100
ASND
$15B
Ascendis Pharma A/S
BULLISH
+100
HALO
$14B
Halozyme Therapeutics, Inc.
BULLISH
+100
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+100
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+100
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+100
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+100
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+100
SEPN
$1.9B
Septerna Inc
BULLISH
+100
COAG
$1.6B
Hemab Therapeutics Holdings, Inc. Common Stock
BULLISH
+100
REGN
$83B
Regeneron Pharmaceuticals, Inc.
BULLISH
+91
EXEL
$16B
Exelixis, Inc.
BULLISH
+91
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
VCEL
$2.2B
Vericel Corporation
BULLISH
+91
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
BULLISH
+91
KLRA
$1.7B
Kailera Therapeutics, Inc.
BULLISH
+91
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+87
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+87
UTHR
$25B
United Therapeutics Corporation
BULLISH
+84
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+84
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
VIR
$1.8B
Vir Biotechnology, Inc.
BULLISH
+82
MAZE
$1.7B
Maze Therapeutics, Inc.
BULLISH
+78
GNMSF
$28B
Genmab A/S
BULLISH
+75
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+75
TGTX
$8.3B
TG Therapeutics, Inc.
BULLISH
+75
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+75
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+75
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+74
NBIX
$15B
Neurocrine Biosciences, Inc.
BULLISH
+68
ERAS
$5.0B
Erasca, Inc.
BULLISH
+68
RARE
$1.5B
Ultragenyx Pharmaceutical Inc.
BULLISH
+68
CSLLY
$134B
CSL Limited
BULLISH
+66
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+66
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+66
XNCR
$1.9B
Xencor, Inc.
BULLISH
+66
TRAX
$1.6B
First Tracks Biotherapeutics Inc
BULLISH
+66
NBTX
$1.5B
Nanobiotix S.A.
BULLISH
+62
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BULLISH
+59
NTLA
$1.6B
Intellia Therapeutics, Inc.
BULLISH
+59
TECH
$11B
Bio-Techne Corporation
BULLISH
+58
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+58
KOD
$5.5B
Kodiak Sciences Inc.
BULLISH
+58
MRNA
$80B
Moderna, Inc.
BULLISH
+56
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ROIV
$26B
Roivant Sciences Ltd.
BULLISH
+50
ABSI
$1.6B
Absci Corporation
BULLISH
+50
XERS
$1.9B
Xeris Biopharma Holdings, Inc.
BULLISH
+49
BBIO
$13B
BridgeBio Pharma, Inc.
BULLISH
+43
ONC
$40B
BeOne Medicines AG
BULLISH
+42
RXRX
$2.0B
Recursion Pharmaceuticals, Inc.
BULLISH
+42
IMCR
$1.6B
Immunocore Holdings plc
BULLISH
+41
COGT
$5.4B
Cogent Biosciences, Inc.
BULLISH
+36
ALMR
$2.1B
Alamar Biosciences, Inc.
BULLISH
+35
VRTX
$133B
Vertex Pharmaceuticals Incorporated
BULLISH
+34
RLAY
$4.0B
Relay Therapeutics, Inc.
BULLISH
+34
DYN
$2.9B
Dyne Therapeutics, Inc.
BULLISH
+33
UCBJY
$58B
UCB S.A.
LEAN BULL
+28
PTGX
$9.0B
Protagonist Therapeutics, Inc.
LEAN BULL
+27
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BULL
+27
ELVN
$3.0B
Enliven Therapeutics, Inc.
LEAN BULL
+18
PHVS
$2.2B
Pharvaris N.V.
LEAN BULL
+18
STOK
$1.6B
Stoke Therapeutics, Inc.
LEAN BULL
+18
BRVE
$1.5B
Braveheart Bio, Inc.
LEAN BULL
+15
PVLA
$1.8B
Palvella Therapeutics, Inc.
LEAN BULL
+11
BEAM
$2.5B
Beam Therapeutics Inc.
LEAN BULL
+10
SRPT
$1.9B
Sarepta Therapeutics, Inc.
NEUTRAL
+9
ANAB
$1.5B
AnaptysBio, Inc.
NEUTRAL
+8
AAVXF
$12B
Abivax S.A.
NEUTRAL
+2
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
TXG
$9.3B
10x Genomics, Inc.
NEUTRAL
+1
ABCL
$3.8B
AbCellera Biologics Inc.
NEUTRAL
+1
LYCA
$1.6B
Lycia Therapeutics Inc.
N/A
0
PHMMF
$1.6B
Pharma Mar, S.A.
NEUTRAL
-3
ADPT
$4.1B
Adaptive Biotechnologies Corporation
NEUTRAL
-7
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
-8
ZBIO
$1.8B
Zenas BioPharma, Inc.
NEUTRAL
-8
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
NEUTRAL
-9
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
EWTX
$4.2B
Edgewise Therapeutics, Inc.
LEAN BEAR
-16
ARGX
$55B
argenx SE
LEAN BEAR
-18
SRRK
$5.0B
Scholar Rock Holding Corporation
LEAN BEAR
-18
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
LEAN BEAR
-18
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
ADRX
$1.9B
ADARx Pharmaceuticals, Inc.
LEAN BEAR
-20
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
LEAN BEAR
-22
CELC
$3.2B
Celcuity Inc.
LEAN BEAR
-22
INCY
$23B
Incyte Corporation
LEAN BEAR
-23
TWST
$9.2B
Twist Bioscience Corporation
LEAN BEAR
-24
NURPF
$1.8B
Neuren Pharmaceuticals Limited
LEAN BEAR
-26
IMNM
$2.1B
Immunome, Inc.
LEAN BEAR
-27
XENE
$3.4B
Xenon Pharmaceuticals Inc.
BEARISH
-31
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-34
TRVI
$1.8B
Trevi Therapeutics, Inc.
BEARISH
-34
QURE
$1.6B
uniQure N.V.
BEARISH
-34
WXIBF
$26B
WuXi Biologics (Cayman) Inc.
BEARISH
-35
MEOBF
$2.0B
Mesoblast Limited
BEARISH
-37
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-40
CLDX
$2.3B
Celldex Therapeutics, Inc.
BEARISH
-40
BCRX
$1.9B
BioCryst Pharmaceuticals, Inc.
BEARISH
-40
CSPHF
$1.4B
CStone Pharmaceuticals
BEARISH
-42
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
IDRSF
$1.4B
Idorsia Ltd
BEARISH
-47
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-48
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-49
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-49
PTCT
$5.1B
PTC Therapeutics, Inc.
BEARISH
-49
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-49
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-49
VERA
$2.0B
Vera Therapeutics, Inc.
BEARISH
-49
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
CGON
$5.5B
CG Oncology Inc.
BEARISH
-58
CRSP
$4.8B
CRISPR Therapeutics AG
BEARISH
-58
PBLS
$3.0B
Parabilis Medicines, Inc.
BEARISH
-58
MLYS
$1.8B
Mineralys Therapeutics, Inc.
BEARISH
-58
GENB
$1.6B
Generate Biomedicines, Inc.
BEARISH
-58
CMPS
$1.6B
COMPASS Pathways plc
BEARISH
-58
IVBXF
$20B
Innovent Biologics, Inc.
BEARISH
-59
CAMRF
$3.7B
Camurus AB
BEARISH
-59
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-60
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
RVMDW
$40B
Revolution Medicines, Inc. Warrant
BEARISH
-66
ALNY
$30B
Alnylam Pharmaceuticals, Inc.
BEARISH
-66
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-66
INVA
$1.5B
Innoviva, Inc.
BEARISH
-66
BMRN
$11B
BioMarin Pharmaceutical Inc.
BEARISH
-69
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-69
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-75
AAPG
$1.4B
Ascentage Pharma Group International
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-78
NUVB
$1.6B
Nuvation Bio Inc.
BEARISH
-78
NVAX
$1.6B
Novavax, Inc.
BEARISH
-78
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-82
RVMD
$40B
Revolution Medicines, Inc.
BEARISH
-84
BNTX
$22B
BioNTech SE
BEARISH
-84
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-84
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-84
PGEN
$2.2B
Precigen, Inc.
BEARISH
-84
JAZZ
$14B
Jazz Pharmaceuticals plc
BEARISH
-87
MDGL
$10B
Madrigal Pharmaceuticals, Inc.
BEARISH
-87
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-87
URGN
$1.7B
UroGen Pharma Ltd.
BEARISH
-87
INSM
$20B
Insmed Incorporated
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
GENSF
$1.8B
Genus plc
BEARISH
-91
OCUL
$1.4B
Ocular Therapeutix, Inc.
BEARISH
-91
SMMT
$12B
Summit Therapeutics Inc.
BEARISH
-100
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-100
BRCTF
$2.6B
BioArctic AB
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| ASND Ascendis Pharma A/S | $15B | 18.2 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| EXEL Exelixis, Inc. | $16B | 19.8 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 142.2 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| UTHR United Therapeutics Corporation | $25B | 19.5 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BULLISH | 511.6 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -52.0 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ROIV Roivant Sciences Ltd. | $26B | -95.9 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 147.5 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.3 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -33.0 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.9 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 174.6 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BULLISH | -1.1 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BULL | 112.0 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | LEAN BULL | 39.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | LEAN BULL | — |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | LEAN BULL | 82.1 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | LEAN BULL | -10.9 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | NEUTRAL | -17.2 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | NEUTRAL | 126.7 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | NEUTRAL | 60.6 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | LEAN BEAR | 160.4 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BEAR | -8.4 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BEAR | 22.2 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -4.1 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 19.6 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 12.8 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 18.2 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.2 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.1 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| INSM Insmed Incorporated | $20B | -23.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 73.8 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | NEUTRAL | 32.2 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| RPRX Royalty Pharma plc | $28B | 27.1 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.5 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.0 |
| LH Labcorp Holdings Inc. | $27B | 27.0 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 19.8 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.8 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| ASND Ascendis Pharma A/S | $15B | 18.2 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 1.7 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| HNGE Hinge Health, Inc. | $9.0B | 84.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 129.6 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 32.8 |
| ALKS Alkermes plc | $7.3B | 110.1 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 48.7 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 43.0 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 103.2 |
| BLCO Bausch + Lomb Corporation | $6.2B | -36.9 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 13.5 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 63.0 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BULLISH | 129.1 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.9 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.8 |
| LFST LifeStance Health Group, Inc. | $4.9B | 101.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 151.9 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| ATRC AtriCure, Inc. | $3.0B | 289.6 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.9 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| GNNDY GN Store Nord A/S | $2.4B | -29.9 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -5.1 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 2.4 |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 4.8 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 3.6 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| EW Edwards Lifesciences Corporation | $51B | 52.1 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| ILMN Illumina, Inc. | $41B | 51.6 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 179.2 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| EXEL Exelixis, Inc. | $16B | 19.8 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.1 |
| GKOS Glaukos Corporation | $11B | -56.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 142.7 |
| HQY HealthEquity, Inc. | $8.6B | 36.3 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 4.5 |
| PACS PACS Group, Inc. | $7.5B | 28.0 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 277.8 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.5 |
| DOCS Doximity, Inc. | $6.0B | 37.2 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.3 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| WAY Waystar Holding Corp. | $5.5B | 38.9 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -28.1 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 92.0 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 64.0 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -23.7 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 78.2 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 142.2 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| ABT Abbott Laboratories | $179B | 38.2 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -18.7 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| UTHR United Therapeutics Corporation | $25B | 19.5 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| GH Guardant Health, Inc. | $23B | -51.1 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 146.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| PODD Insulet Corp. | $10B | 27.9 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.3 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.6 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 12.1 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| BLLN BillionToOne, Inc. | $5.1B | 166.9 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| MCK McKesson Corporation | $117B | 25.8 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 20.7 |
| WILYY Demant A/S | $12B | 46.8 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HAE Haemonetics Corporation | $5.4B | 58.5 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 134.1 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| PGNY Progyny, Inc. | $2.2B | 28.5 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.2 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| NTRA Natera, Inc. | $58B | -303.0 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.6 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| SNN Smith & Nephew plc | $13B | 19.7 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| PEN Penumbra, Inc. | $13B | 79.3 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.1 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -18.5 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| GILD Gilead Sciences, Inc. | $193B | -60.9 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.2 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.4 |
| CVS CVS Health Corp. | $120B | 23.8 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 11.2 |
| SYK Stryker Corporation | $118B | 31.0 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -21.0 |
| SOAGY Sartorius AG ADR | $92B | 92.0 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 16.0 |
| WAT Waters Corporation | $45B | 116.7 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| BIIB Biogen Inc. | $37B | 44.4 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| VTRS Viatris Inc. | $21B | -52.2 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| ALGN Align Technology, Inc. | $11B | 26.4 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.4 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.6 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -41.1 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 52.7 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -44.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 194.2 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| CAH Cardinal Health, Inc. | $58B | 34.0 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.9 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| A Agilent Technologies, Inc. | $49B | 35.1 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| IQV IQVIA Holdings Inc. | $46B | 32.9 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| ICLR ICON Public Limited Company | $14B | 42.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.7 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.1 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.2 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 1.8 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | -0.3 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.4 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| DGX Quest Diagnostics Incorporated | $27B | 23.7 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 33.1 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 14.7 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BULLISH | 511.6 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -52.0 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 7 | BULLISH | 101.6 |
| RVTY Revvity, Inc. | $18B | 76.9 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.6 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -2.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 12.2 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.9 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| GRAL GRAIL Inc. | $5.9B | -15.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| AMBBY Ambu A/S | $3.2B | 41.6 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.1 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -16.0 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.2 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.7 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.5 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| ROIV Roivant Sciences Ltd. | $26B | -95.9 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BMXXY bioMérieux S.A. | $12B | 22.8 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| GMED Globus Medical, Inc. | $11B | 20.4 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 29.8 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.5 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 147.5 |
| ELV Elevance Health Inc. | $95B | 17.9 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 23.7 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -17.1 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| EKTAY Elekta AB (publ) | $2.2B | -60.9 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 9.3 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.3 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| BRKR Bruker Corporation | $8.8B | -86.2 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 55.9 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | BULLISH | -5.9 |
| RDNT RadNet, Inc. | $5.5B | -277.5 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BULLISH | -11.8 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -33.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.7 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.9 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | BULLISH | -15.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BULLISH | -13.8 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 174.6 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BULLISH | -1.1 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 73.8 |
| HUM Humana Inc. | $51B | 38.9 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 27.8 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| SHC Sotera Health Company | $5.2B | 32.2 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | LEAN BULL | -48.2 |
| NVST Envista Holdings Corp | $3.8B | 40.2 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.2 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -7.9 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | LEAN BULL | 22.7 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BULL | 112.0 |
| NEOG Neogen Corporation | $2.7B | -49.3 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.5 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | LEAN BULL | 39.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 19.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | LEAN BULL | 60.4 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | LEAN BULL | — |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | LEAN BULL | 82.1 |
| TEM Tempus AI, Inc. | $12B | -50.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | LEAN BULL | -19.1 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | LEAN BULL | -10.9 |
| NEO NeoGenomics, Inc. | $2.2B | -43.6 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | LEAN BULL | 61.9 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -17.4 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | NEUTRAL | -17.2 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | NEUTRAL | 32.2 |
| CLCGY Clicks Group Limited | $3.1B | 15.8 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | NEUTRAL | -37.3 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.6 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | NEUTRAL | 34.7 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | NEUTRAL | 62.6 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | NEUTRAL | -2.0 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| HCA HCA Healthcare, Inc. | $102B | 53.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| TCHBF Tecan Group AG | $3.5B | -26.5 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | NEUTRAL | 45.2 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | NEUTRAL | 126.7 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| DVA DaVita Inc. | $12B | 15.6 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | NEUTRAL | 40.7 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | NEUTRAL | 60.6 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | NEUTRAL | 50.4 |
| CHE Chemed Corporation | $6.7B | 25.4 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | NEUTRAL | 16.6 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.4 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | NEUTRAL | 46.7 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.2 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BEAR | -23.8 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | LEAN BEAR | 32.6 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | LEAN BEAR | -3.2 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | LEAN BEAR | 78.7 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | LEAN BEAR | 160.4 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| MOH Molina Healthcare, Inc. | $11B | -323.5 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | LEAN BEAR | 22.1 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BEAR | -8.4 |
| CLOV Clover Health Investments, Corp. | $2.4B | -114.2 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | LEAN BEAR | 21.2 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BEAR | 22.2 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -4.1 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | LEAN BEAR | -37.5 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 74.0 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 19.6 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.1 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -24.8 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| AXGN AxoGen, Inc. | $2.2B | -56.1 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | BEARISH | 106.2 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BEARISH | -6.5 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.6 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 38.8 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.7 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -311.9 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 12.8 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| RSMDF ResMed Inc. | $36B | 24.1 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.0 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | BEARISH | -13.4 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BEARISH | 68.8 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BEARISH | -15.7 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -28.8 |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| RGEN Repligen Corporation | $11B | -831.3 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BEARISH | 5.7 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.7 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -17.4 |
| THC Tenet Healthcare Corporation | $22B | 10.0 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 24.5 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.2 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -22.5 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.3 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| ENSG The Ensign Group, Inc. | $10B | 25.8 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -8.9 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 18.2 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.2 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| DXCM DexCom, Inc. | $29B | 30.5 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.7 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.7 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -42.7 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.9 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.8 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| NHC National HealthCare Corporation | $3.7B | 23.5 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 72.6 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.1 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 168.0 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 20.8 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| INSM Insmed Incorporated | $20B | -23.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.1 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.8 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 7.7 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| MDLN Medline Inc. | $30B | 37.9 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.8 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -46.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
DNTH vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F